Skip to Content

Viatris Inc

VTRS: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$46.00KklWshqprj

Viatris Earnings: New Launches and Stabilized Generics Prove Enough To Offset Challenges

No-moat Viatris reported second-quarter results that were slightly ahead of our expectations. Total sales were down 4.8% year over year but up 1.5% on an operational basis (excluding foreign exchange and divestiture impacts). Our assumptions for the second half of the year remain largely the same, and we maintain our $13 fair value estimate.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of VTRS so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center